Updated July 2026. Field status: No licensed hepatitis C vaccine exists. Highly effective direct-acting antivirals (DAAs) achieve cure in >95% of patients, but a preventive vaccine is still critical for reaching WHO's 2030 elimination goal — DAAs cannot address the missing prevention arm, especially in people who inject drugs (PWID). The most advanced candidate to date was NIAID's ChAd3-NSmut + MVA-NSmut prime-boost vaccine, tested in a large placebo-controlled Phase 1/2 trial in high-risk PWID; the trial demonstrated safety and immunogenicity but did not prevent chronic HCV infection. Current pipeline focus has shifted to next-generation approaches: adjuvanted recombinant E1E2 glycoprotein vaccines (CHO-cell expressed), self-amplifying RNA and mRNA-encoded E1/E2 (leveraging COVID-19 mRNA success), and improved viral vector candidates. NIAID hosted a March 2022 symposium ("Vaccines against hepatitis C virus: Harnessing Immunity to Eliminate Global Hepatitis C") that catalyzed several new Phase 1 initiatives. WHO 2030 elimination targets — 90% reduction in new infections and 65% reduction in mortality — remain achievable only with combined DAA scale-up + preventive vaccine deployment for PWID populations.
Tracking HCV Vaccine Development - No Licensed Vaccine Yet
Hepatitis C Virus (HCV) chronically infects 58 million people globally, causing 290,000 deaths annually from cirrhosis and liver cancer. Unlike Hepatitis A and B, no vaccine exists for Hepatitis C despite decades of research. The challenge: HCV has extraordinary genetic diversity (8 genotypes, 90+ subtypes), rapid mutation rates, and sophisticated immune evasion mechanisms. However, breakthrough Direct-Acting Antivirals (DAAs) cure >95% of infections, reducing vaccine urgency for treatment but not prevention. Vaccine development continues because: (1) 1.5M new infections yearly, (2) many lack treatment access, (3) reinfection occurs post-cure in high-risk groups (PWID), (4) vaccine would be cost-effective for prevention. This tracker monitors promising Phase 2 candidates using novel strategies: broadly neutralizing antibody induction, T-cell focused vaccines, and universal epitope targeting.